Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Female Urogenital Diseases and Pregnancy Complications

ClinicalTrials.gov lists 37,418 trials for Female Urogenital Diseases and Pregnancy Complications or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 499.

MeSH D005261 Urogenital Diseases C12
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 3,190 Phase 1/2 Phase 1/2 1,276 Phase 2 Phase 2 4,664 Phase 2/3 Phase 2/3 519 Phase 3 Phase 3 2,847 Phase 4 Phase 4 2,456 Not applicable Not applicable 12,365 Observational Observational 10,051 Phase 1 Phase 1 3,190 Phase 1/2 Phase 1/2 1,276 Phase 2 Phase 2 4,664 Phase 2/3 Phase 2/3 519 Phase 3 Phase 3 2,847 Phase 4 Phase 4 2,456 Not applicable Not applicable 12,365 Observational Observational 10,051

Trials per phase (log scale)

2 more sections with rows

7 of the 37,418 trials are tagged with Female Urogenital Diseases and Pregnancy Complications itself; the rest are tagged with a narrower condition beneath it.

Get the Female Urogenital Diseases and Pregnancy Complications report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Female Urogenital Diseases and Pregnancy Complications trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 78 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 2,379

1990: 12 trials (Observational 5, Not applicable 3, Phase 2 3, Phase 1/2 1) 1991: 13 trials (Observational 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1 2) 1992: 21 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2 4, Phase 1 3) 1993: 26 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 7) 1994: 27 trials (Observational 11, Phase 3 5, Phase 2/3 2, Phase 2 2, Phase 1/2 2, Phase 1 5) 1995: 38 trials (Observational 10, Not applicable 5, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 1) 1996: 62 trials (Observational 10, Not applicable 6, Phase 4 2, Phase 3 17, Phase 2 15, Phase 1/2 4, Phase 1 8) 1997: 88 trials (Observational 13, Not applicable 8, Phase 4 4, Phase 3 21, Phase 2/3 1, Phase 2 23, Phase 1/2 5, Phase 1 13) 1998: 119 trials (Observational 14, Not applicable 12, Phase 4 2, Phase 3 23, Phase 2 48, Phase 1/2 2, Phase 1 18) 1999: 156 trials (Observational 33, Not applicable 11, Phase 4 1, Phase 3 34, Phase 2/3 1, Phase 2 49, Phase 1/2 6, Phase 1 21) 2000: 207 trials (Observational 42, Not applicable 23, Phase 4 8, Phase 3 32, Phase 2/3 3, Phase 2 60, Phase 1/2 12, Phase 1 27) 2001: 250 trials (Observational 37, Not applicable 33, Phase 4 14, Phase 3 36, Phase 2/3 5, Phase 2 77, Phase 1/2 16, Phase 1 32) 2002: 293 trials (Observational 43, Not applicable 43, Phase 4 34, Phase 3 52, Phase 2/3 6, Phase 2 83, Phase 1/2 12, Phase 1 20) 2003: 414 trials (Observational 84, Not applicable 55, Phase 4 47, Phase 3 71, Phase 2/3 4, Phase 2 101, Phase 1/2 23, Phase 1 29) 2004: 527 trials (Observational 99, Not applicable 96, Phase 4 67, Phase 3 82, Phase 2/3 8, Phase 2 119, Phase 1/2 22, Phase 1 34) 2005: 650 trials (Other 1, Observational 119, Not applicable 133, Phase 4 74, Phase 3 79, Phase 2/3 12, Phase 2 147, Phase 1/2 29, Phase 1 56) 2006: 817 trials (Observational 162, Not applicable 167, Phase 4 72, Phase 3 102, Phase 2/3 13, Phase 2 198, Phase 1/2 33, Phase 1 70) 2007: 856 trials (Observational 192, Not applicable 161, Phase 4 78, Phase 3 112, Phase 2/3 22, Phase 2 181, Phase 1/2 22, Phase 1 88) 2008: 958 trials (Observational 236, Not applicable 208, Phase 4 103, Phase 3 106, Phase 2/3 22, Phase 2 169, Phase 1/2 22, Phase 1 92) 2009: 1,005 trials (Observational 267, Not applicable 210, Phase 4 113, Phase 3 109, Phase 2/3 29, Phase 2 141, Phase 1/2 38, Phase 1 98) 2010: 1,040 trials (Other 1, Observational 273, Not applicable 237, Phase 4 103, Phase 3 88, Phase 2/3 22, Phase 2 172, Phase 1/2 40, Phase 1 104) 2011: 1,126 trials (Observational 293, Not applicable 294, Phase 4 108, Phase 3 101, Phase 2/3 19, Phase 2 148, Phase 1/2 31, Phase 1 132) 2012: 1,239 trials (Other 2, Observational 337, Not applicable 359, Phase 4 117, Phase 3 118, Phase 2/3 11, Phase 2 152, Phase 1/2 43, Phase 1 100) 2013: 1,216 trials (Other 2, Observational 336, Not applicable 365, Phase 4 118, Phase 3 97, Phase 2/3 15, Phase 2 133, Phase 1/2 38, Phase 1 112) 2014: 1,373 trials (Observational 357, Not applicable 479, Phase 4 99, Phase 3 94, Phase 2/3 22, Phase 2 141, Phase 1/2 58, Phase 1 123) 2015: 1,502 trials (Observational 380, Not applicable 498, Phase 4 122, Phase 3 130, Phase 2/3 26, Phase 2 155, Phase 1/2 51, Phase 1 140) 2016: 1,662 trials (Other 1, Observational 465, Not applicable 575, Phase 4 118, Phase 3 115, Phase 2/3 26, Phase 2 174, Phase 1/2 59, Phase 1 129) 2017: 1,759 trials (Observational 464, Not applicable 622, Phase 4 117, Phase 3 115, Phase 2/3 32, Phase 2 192, Phase 1/2 54, Phase 1 163) 2018: 1,881 trials (Observational 490, Not applicable 735, Phase 4 112, Phase 3 129, Phase 2/3 18, Phase 2 220, Phase 1/2 56, Phase 1 121) 2019: 2,056 trials (Observational 621, Not applicable 746, Phase 4 119, Phase 3 130, Phase 2/3 29, Phase 2 186, Phase 1/2 57, Phase 1 168) 2020: 1,970 trials (Other 1, Observational 642, Not applicable 711, Phase 4 102, Phase 3 108, Phase 2/3 12, Phase 2 190, Phase 1/2 51, Phase 1 153) 2021: 2,259 trials (Observational 705, Not applicable 832, Phase 4 102, Phase 3 126, Phase 2/3 20, Phase 2 209, Phase 1/2 85, Phase 1 180) 2022: 2,255 trials (Observational 702, Not applicable 862, Phase 4 92, Phase 3 117, Phase 2/3 23, Phase 2 211, Phase 1/2 67, Phase 1 181) 2023: 2,310 trials (Observational 667, Not applicable 932, Phase 4 94, Phase 3 108, Phase 2/3 31, Phase 2 215, Phase 1/2 85, Phase 1 178) 2024: 2,359 trials (Observational 710, Not applicable 953, Phase 4 97, Phase 3 98, Phase 2/3 35, Phase 2 202, Phase 1/2 77, Phase 1 187) 2025: 2,379 trials (Observational 614, Not applicable 1,034, Phase 4 96, Phase 3 114, Phase 2/3 28, Phase 2 220, Phase 1/2 89, Phase 1 184)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2,143
2025 2,379
2024 2,359
2023 2,310
2022 2,255
2021 2,259
2020 1,970
2019 2,056
2018 1,881
2017 1,759

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 2,700 trials starting in 2026 and about 2,400 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 3,548 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 21,694 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Female Urogenital Diseases and Pregnancy Complications trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 3,190
Phase 1/2 1,276
Phase 2 4,664
Phase 2/3 519
Phase 3 2,847
Phase 4 2,456
Not applicable 12,365
Observational 10,051
Expanded access 47
Unknown 3

How many Female Urogenital Diseases and Pregnancy Complications trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1,917
Recruiting 4,603
Enrolling by invitation 266
Active, not recruiting 1,594
Available 13

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Female Urogenital Diseases and Pregnancy Complications trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 499
AstraZeneca 210
Pfizer 208
Bayer 188
GlaxoSmithKline 180

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Female Urogenital Diseases and Pregnancy Complications? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 507
PEMBROLIZUMAB 339
Cytoxan 219
NIVOLUMAB 203
MisoprostoL 127

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 452
Cisplatin 1 370
Bevacizumab 1 306
Gemcitabine/Gemzar 294
1% Metformin 250

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Female Urogenital Diseases and Pregnancy Complications trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 7,000 763
Major Adverse Cardiovascular Events 6,762 1
Major Adverse Kidney Events 5,557 1
Stillbirth/neonatal death 5,079 1
Sepsis 3,632 666

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages